Podcast

Making Headway in GI Malignancies in Miami

Author(s):

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, faculty from the Florida Society of Clinical Oncology discussed the novel agents that are generating excitement in advanced hepatocellular carcinoma and cholangiocarcinoma and the novel therapies and strategies that are propelling progress in gastric cancer.

Moreover, panelists shed light on the use of molecular testing in colorectal cancer and the current and investigational treatment strategies in the relapsed/refractory setting. Other key topics included remaining challenges with staging in pancreatic cancer, unanswered questions in the localized setting, and the benefits of olaparib in the metastatic setting.

Interested in attending an upcoming OncLive® State of the Science Summit in your area? Register today.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.